News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Uroplasty, Inc. (UPI) to Participate in Two Upcoming Conferences


8/8/2012 12:32:35 PM

MINNEAPOLIS, Aug. 8, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced its participation in two upcoming conferences.

Wedbush Securities PacGrow Life Sciences Conference
Date: Tuesday, August 14, 2012
Time: 3:40 pm ET
Location: New York, NY
David Kaysen, President and CEO, will present the Company's strategy and recent corporate developments.

Attendance at the conference is by invitation only. A live audio webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at http://wsw.com/webcast/wedbush21/upi/, or through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

32nd Annual Canaccord Growth Conference
Date: Wednesday, August 15, 2012
Location: Boston, MA
David Kaysen will meet with interested investors in a series of one-on-one meetings.

These meetings will not be webcast.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:


Uroplasty, Inc.

EVC Group

David Kaysen, President and CEO, or

Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349

Medi Jiwani, Vice President, CFO, Treasurer

Chris Gale (Media), 646.201.5431

952.426.6140


SOURCE Uroplasty, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES